Our EU referendum poll: the results are in
31 March 2016 | By Victoria White, Drug Target Review
We asked readers of if they agreed with BIA that the UK pharmaceutical industries are stronger in the EU. The results of that poll are now in...
List view / Grid view
Articles
Explaining CAR T-cell therapy
23 March 2016 | By Dr John Maher, Principal Investigator, National Institute for Health Research (NIHR) Biomedical Research Centre (BRC) at Guy’s and St Thomas’ and Kings College London
Here, Dr John Maher of the NIHR BRC at Guy's and St Thomas' and Kings College London discusses CAR T-cell therapy and the exciting frontier the technique has opened up in the battle against cancer...
Drug Target Review – Issue #1 2016
17 March 2016 | By Drug Target Review
Included in this issue: Microfluidics, Protein Expression, Drug Targets, Biomarkers, Oncology, Assays, Antibodies, and much more...
Antibodies In-Depth Focus 2016
In this Antibodies In-depth Focus: Antibody fragment technology and avian IgY antibodies: a powerful combination; plus the challenges with antibody-based targeting of VEGF...
Assays In-Depth Focus 2016
In this Assays In-Depth Focus: "Finding a cure for neglected tropical diseases with cell-based assays", plus "The relevance of homogeneous radiometric assays in modern drug discovery"...
Using computational models to aid drug discovery
Long term success for pharmaceutical businesses depends upon harnessing the best tools available to bring safe and effective medicines to market at a competitive price, and to be truly successful, for such drugs to be first in class.
Drug Targets In-Depth Focus 2016
17 March 2016 | By Drug Target Review
In this Drug Targets In-Depth Focus: "The alarming increase in antibioticresistant bacteria", plus "Computational methods for drug repositioning"; and "An overview of Alzheimer’s disease drug targets"...
Interview with Amrik Basran, Chief Scientific Officer at Avacta Life Sciences
Caroline Richards, Editor of Drug Target Review, asks Amrik Basran, Chief Scientific Officer at Avacta Life Sciences, to provide his views on Affimer® technology...
Microfluidics: The fur-free way towards personalised medicine in cancer therapy
Microfluidic technology has great potential for complementing and, in some instances, replacing the use of animal models in the testing of medicines and in developing personalised treatments for cancer patients.
Pushing the limits of protein expression with miRNAs
Biopharmaceuticals are highly complex protein drugs such as antibodies, cytokines and peptide hormones, which are used for a variety of indication areas, including immunology, neurology, metabolic diseases and cancer. These modern protein drugs may hinder progression of a disease, ease symptoms or assure – in the case of chronic diseases…
Strategies for identifying predictive biomarkers of non-alcoholic fatty liver disease
Non-alcoholic fatty liver disease (NAFLD), a consequence of sedentary life styles and high fat diets, has an estimated prevalence of about 30% in western countries. It is associated with insulin resistance, obesity, glucose intolerance and drug toxicity. Additionally, polymorphisms within genes such as PNPLA3, TM6SF2, APOC3, NCAN and PPP1R3B correlate…
Classifying brain tumours to improve diagnoses
Brain tumours are complex cancer types, arising in many unique forms, each having varying survival rates and differing methods of treatment. Many brain tumours are difficult to clearly diagnose, leading to poor patient prognoses. Although they are mainly diagnosed by analysing morphological appearance, this does not closely correlate with the…
UK life sciences are stronger in the EU, says BioIndustry Association
16 March 2016 | By Steve Bates, BioIndustry Association (BIA) Chief Executive
Here, Steve Bates, Chief Executive of the BioIndustry Association (BIA), makes a case for the UK remaining in the EU from the perspective of the life sciences sector...
Browsing for drug targets
8 March 2016 | By Edward D. Zanders, PharmaGuide Ltd, Cambridge, UK
Here, Edward D. Zanders explains his motivation behind writing ‘Human Drug Targets a Compendium for Pharmaceutical Discovery’ - a collection of current and potential drug targets mapped to human genes curated by the HGNC...
The case for data analytics in proof of concept studies
26 February 2016 | By Rodrigo Barnes, Chief Technology Officer at Aridhia
Here, Rodrigo Barnes, Chief Technology Officer at Aridhia, discusses how data analytics can add value to proof of concept trials...
